Format

Send to

Choose Destination
Transl Lung Cancer Res. 2014 Apr;3(2):84-8. doi: 10.3978/j.issn.2218-6751.2014.02.06.

Targeted therapy in NSCLC driven by HER2 insertions.

Author information

1
Department of Oncology, University Hospital of Vaudois (CHUV), Lausanne, Switzerland.

Abstract

HER2 mutations, largely exon 20 in-frame insertions, have been described as an oncogenic driver alteration in 1% to 4% of NSCLC, exclusively in adenocarcinoma histology. The prognostic implication of these alterations is not known. Phase I and II trial data suggest that afatinib, neratinib and dacomitinib have some activity in this molecular subgroup. No comparative data, or any data regarding the activity of pertuzumab or trastuzumab-emtansine is available. HER2 deregulation either by protein overexpression or gene amplification, has little clinical relevance to date, as trials investigating trastuzumab activity merely suggest a benefit in the very small minority of patients whose tumor highly overexpresses HER2, a subpopulation that amounts to 2% to 6% of mostly adenocarcinomas.

KEYWORDS:

HER2 mutations; afatinib; dacomitinib; irreversible pan HER-receptor inhibitor; lung cancer

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center